Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial

This multicenter randomized clinical trial evaluated whether the addition of afamelanotide (an α-MSH analogue) to NB-UV-B (narrowband ultraviolet B) phototherapy could improve repigmentation in patients with vitiligo, an autoimmune condition that causes progressive skin depigmentation. The study included 55 patients with Fitzpatrick skin types III-VI and non-segmental vitiligo.

Participants were randomized to receive NB-UV-B phototherapy alone or combined with subcutaneous afamelanotide implants administered monthly for 6 months. Repigmentation was assessed by standardized clinical photography and computerized analysis of the depigmented area.

The results demonstrated that the combination of afamelanotide with NB-UV-B produced significantly greater and faster repigmentation compared to phototherapy alone, particularly in the face and upper limb areas. The onset of repigmentation occurred earlier in the combination group, and the extent of repigmentation at the end of the study was greater.

The proposed synergistic mechanism is that afamelanotide stimulates surviving melanocytes at the edges of lesions and in follicular reservoirs to produce more melanin, while NB-UV-B provides additional stimulus for melanocyte migration and differentiation. This study represented an important advance in the treatment of vitiligo, a condition with historically limited therapeutic options that significantly impacts patients' quality of life.